New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:20 EDTEWEdwards Lifesciences reports positive data on Sapien 3 valve
Edwards Lifesciences announced that the first data on its most advanced commercially available transcatheter aortic heart valve, the Edwards SAPIEN 3 valve, were presented in a late-breaking clinical trial session at EuroPCR 2014 by John Webb, director of interventional cardiology and cardiac catheterization laboratories at St. Paul's Hospital, Vancouver, and professor of cardiology at the University of British Columbia. The presentation concluded that outcomes at 30 days were excellent. Transfemoral SAPIEN 3 implantation was associated with a very low mortality of 2.1%, a stroke rate of 1.0%, and very few access-site complications.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
19:16 EDTEWOn The Fly: After Hours Movers
Subscribe for More Information
16:19 EDTEWEdwards Lifesciences sees Q2 EPS $1.00-$1.10, consensus $1.05
Subscribe for More Information
16:18 EDTEWEdwards Lifesciences narrows FY15 EPS view to $4.10-$4.30, consensus $4.21
Subscribe for More Information
16:17 EDTEWEdwards Lifesciences reports Q1 EPS $1.12, consensus $1.04
Subscribe for More Information
15:00 EDTEWNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use